Endometrial carcinomas with POLE exonuclease domain mutations have a favorable prognosis

Clinical Cancer Research

Volumn 22, Issue 12, 2016, Pages 2865-2873

  McConechy, Melissa K ^a   Talhouk, Aline ^a   Leung, Samuel ^b   Chiu, Derek ^c   Yang, Winnie ^a   Senz, Janine ^a   Reha Krantz, Linda J ^d   Lee, Cheng Han ^d   Huntsman, David G ^a,b,c   Gilks, C Blake ^a,b   McAlpine, Jessica N ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SPECIFIC SURVIVAL; ENDOMETRIUM CARCINOMA; FEMALE; GENE; GENE FREQUENCY; GENE SEQUENCE; GENETIC ASSOCIATION; GERMLINE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; POLE GENE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SOMATIC MUTATION; CANCER GRADING; ENDOMETRIOID CARCINOMA; ENDOMETRIUM; GENETICS; LYMPH NODE METASTASIS; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; PROGNOSIS;

DNA DIRECTED DNA POLYMERASE ALPHA; POLE PROTEIN, HUMAN; POLY ADP RIBOSE BINDING PROTEIN; TUMOR MARKER;

AGED; BIOMARKERS, TUMOR; CARCINOMA, ENDOMETRIOID; DISEASE-FREE SURVIVAL; DNA POLYMERASE II; ENDOMETRIUM; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; MUTATION; NEOPLASM GRADING; POLY-ADP-RIBOSE BINDING PROTEINS; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84975063314     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-2233     Document Type: Article

References (45)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 . Lyon, France: ; 2010. Available from: http://globocan.iarc.fr.
3. Benedet JL, Bender H, Jones H3rd, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 2000;70:209-62.
4. Kurman RJ, International Agency for Research on Cancer, World Health Organization. WHO classification of tumours of female reproductive organs. 4th ed. Lyon: International Agency for Research on Cancer; 2014.
5. Colombo N, Preti E, Landoni F, Carinelli S, Colombo A, Marini C, et al. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2013;24:33-8.
6. Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Warlam-Rodenhuis CC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post operative radiation therapy in endometrial carcinoma. Lancet 2000;355:1404-11.
7. Kwon JS, Qiu F, Saskin R, Carey MS. Are uterine risk factors more important than nodal status in predicting survival in endometrial cancer? Obstet Gynecol 2009;114:736-43.
8. Gilks CB, Oliva E, Soslow R. Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma. Modern Pathol 2011;24:248A-A.
9. Murali R, Soslow RA, Weigelt B. Classification of endometrial carcinoma: more than two types. Lancet Oncol 2014;15:e268-78.
10. Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013;497:67-73.
11. Church DN, Stelloo E, Nout RA, Valtcheva N, Depreeuw J, ter Haar N, et al. Prognostic significance of POLE proofreading mutations in endometrial cancer. J Natl Cancer Inst 2015;107:402.
12. Meng B, Hoang LN, McIntyre JB, Duggan MA, Nelson GS, Lee CH, et al. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium. Gynecol Oncol 2014;134:15-9.
13. Church DN, Briggs SE, Palles C, Domingo E, Kearsey SJ, Grimes JM, et al. DNA polymerase epsilon and delta exonuclease domain mutations in endometrial cancer. Hum Mol Genet 2013;22:2820-8.
14. Palles C, Cazier JB, Howarth KM, Domingo E, Jones AM, Broderick P, et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet 2013;45:136-44.
15. Yoshida R, Miyashita K, Inoue M, Shimamoto A, Yan Z, Egashira A, et al. Concurrent genetic alterations in DNA polymerase proofreading and mismatch repair in human colorectal cancer. Eur J Hum Genet 2011;19:320-5.
16. Erson-Omay EZ, Caglayan AO, Schultz N, Weinhold N, Omay SB, Ozduman K, et al. Somatic POLE mutations cause an ultramutated giant cell high-grade glioma subtype with better prognosis. Neuro-oncology 2015.
17. Pursell ZF, Isoz I, Lundstrom EB, Johansson E, Kunkel TA. Yeast DNA polymerase epsilon participates in leading-strand DNA replication. Science 2007;317:127-30.
18. Nick McElhinny SA, Gordenin DA, Stith CM, Burgers PM, Kunkel TA. Division of labor at the eukaryotic replication fork. Mol Cell 2008;30:137-44.
19. Kunkel TA. DNA replication fidelity. J Biol Chem 2004;279:16895-8.
20. Reha-Krantz LJ. DNA polymerase proofreading: Multiple roles maintain genome stability. Biochimica et biophysica acta 2010;1804:1049-63.
21. Korona DA, Lecompte KG, Pursell ZF. The high fidelity and unique error signature of human DNA polymerase epsilon. Nucleic Acids Res 2011;39:1763-73.
22. Schmitt MW, Matsumoto Y, Loeb LA. High fidelity and lesion bypass capability of human DNA polymerase delta. Biochimie 2009;91:1163-72.
23. Shinbrot E, Henninger EE, Weinhold N, Covington KR, Goksenin AY, Schultz N, et al. Exonuclease mutations in DNA polymerase epsilon reveal replication strand specific mutation patterns and human origins of replication. Genome Res 2014;24:1740-50.
24. Billingsley CC, Cohn DE, Mutch DG, Stephens JA, Suarez AA, Goodfellow PJ. Polymerase varepsilon (POLE) mutations in endometrial cancer: Clinical outcomes and implications for Lynch syndrome testing. Cancer 2015;121:386-94.
25. Garcia-Dios DA, Lambrechts D, Coenegrachts L, Vandenput I, Capoen A, Webb PM, et al. High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma. Gynecol Oncol 2013;128:327-34.
26. Wild PJ, Ikenberg K, Fuchs TJ, Rechsteiner M, Georgiev S, Fankhauser N, et al. p53 suppresses type II endometrial carcinomas in mice and governs endometrial tumour aggressiveness in humans. EMBO Mol Med 2012;4:808-24.
27. Nout RA, Smit VT, Putter H, Jurgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 2010;375:816-23.
28. Bakhsh S, Kinloch M, Hoang LN, Soslow R, Kobel M, Lee CH, et al. Histopathological features of endometrial carcinomas associated with POLE mutations: implications for decisions about adjuvant therapy. Histopathology 2015 Sep 28. [Epub ahead of print].
29. Stelloo E, Bosse T, Nout RA, MacKay HJ, Church DN, Nijman HW, et al. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. Mod Pathol 2015;28:836-44.
30. Hoang LN, McConechy MK, Kobel M, Han G, Rouzbahman M, Davidson B, et al. Histotype-genotype correlation in 36 high-grade endometrial carcinomas. Am J Surg Pathol 2013;37:1421-32.
31. Gallo ML, O'Hara AJ, Rudd ML, Urick ME, Hansen NF, O'Neil NJ, et al. Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat Genet 2012;44:1310-5.
32. Zhao S, Choi M, Overton JD, Bellone S, Roque DM, Cocco E, et al. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proc Natl Acad Sci U S A 2013;110:2916-21.
33. Bendifallah S, Canlorbe G, Collinet P, Arsene E, Huguet F, Coutant C, et al. Just how accurate are the major risk stratification systems for early-stage endometrial cancer? Brit J Cancer 2015;112:793-801.
34. Murphy K, Darmawan H, Schultz A, da Silva EF, Reha-Krantz LJ. A method to select for mutator DNA polymerase ds in Saccharomyces cerevisiae. Genome 2006;49:403-10.
35. Lange SS, Takata K, Wood RD. DNA polymerases and cancer. Nat Rev Cancer 2011;11:96-110.
36. Reha-Krantz LJ. Locations of amino acid substitutions in bacteriophage T4 tsL56 DNA polymerase predict an N-terminal exonuclease domain. J Virol 1989;63:4762-6.
37. Albertson TM, Ogawa M, Bugni JM, Hays LE, Chen Y, Wang Y, et al. DNA polymerase epsilon and delta proofreading suppress discrete mutator and cancer phenotypes in mice. Proc Natl Acad Sci U S A 2009;106:17101-4.
38. Fox EJ, Loeb LA. Lethal mutagenesis: targeting the mutator phenotype in cancer. Sem Cancer Biol 2010;20:353-9.
39. van Gool IC, Eggink FA, Freeman-Mills L, Stelloo E, Marchi E, de Bruyn M, et al. POLE proofreading mutations elicit an anti-tumor immune response in endometrial cancer. Clin Cancer Res 2015;21:3347-55.
40. Nelson BH, McAlpine JN. The more tumors change, the more they stay tame: Do T cells keep POLE ultramutated endometrial carcinomas in check? Gynecol Oncol 2015;138:1-2.
41. Bellone S, Centritto F, Black J, Schwab C, English D, Cocco E, et al. Polymerase e (POLE) ultra-mutated tumors induce robust tumor-specific CD4 + T cell responses in endometrial cancer patients. Gynecol Oncol 2015;138:11-7.
42. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372:2509-20.
43. Stenzinger A, Pfarr N, Endris V, Penzel R, Jansen L, Wolf T, et al. Mutations in POLE and survival of colorectal cancer patients-link to disease stage and treatment. Cancer Med 2014;3:1527-38.
44. Horlings HM, Shah SP, Huntsman DG. Using somatic mutations to guide treatment decisions: Context matters. JAMA Oncol 2015;1:275-6.
45. Talhouk A, McConechy MK, Leung S, Li-Chang HH, Kwon JS, Melnyk N, et al. A clinically applicable molecular-based classification forendometrial cancers. Br J Cancer 2015;113:299-310.